CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities:
Net Loss	$ (34,128,031)	$ (32,125,858)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	788,175	650,142
Stock-based Compensation	4,951,777	4,387,554
Research and Development - Licenses Acquired (Related Party)	0	1,100,000
Increase in Inventory Reserves	1,271,000	8,784,000
Amortization of Right of Use Asset	1,864,538
Loss on Disposal of Assets	4,561	4,752
Realized (Gain) Loss on Sale of Investments Available-for-Sale	(30,182)	222,338
Foreign Currency Translation Adjustment	(773)	(10,762)
Changes in Assets and Liabilities:
Decrease (Increase) in Insurance Receivable	371,217	(371,217)
Decrease (Increase) in Accounts Receivable, net	2,776,789	(623,948)
Decrease (Increase) in Inventory	316,872	(835,641)
Decrease (Increase) in Other Assets	933,960	(165,712)
(Decrease) Increase in Accounts Payable	(1,473,648)	269,912
(Decrease) Increase in Settlement Payable	(312,668)	416,668
Decrease in Lease Liability	(1,803,048)
(Decrease) Increase in Other Liabilities	(532,222)	271,889
Decrease in Deferred License Revenue	(2,252,865)	(2,394,051)
Changes in Assets and Liabilities	(1,975,613)	(3,432,100)
Cash Used In Operating Activities	(27,254,548)	(20,419,934)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	(41,677,994)	(20,178,127)
Sale of Investments Available-for-Sale	38,265,664	33,895,481
Purchase of Equipment	(587,452)	(744,256)
Purchase of Research and Development Licenses (Related Party)	(750,000)	(250,000)
Proceeds on Sale of Assets	0	400
Cash (Used in) Provided By Investing Activities	(4,749,782)	12,723,498
Cash Flows From Financing Activities:
Payments on Short Term Note Payable	(1,145,132)	0
Proceeds from the Exercise of Employee Stock Options, Net of Tax	147,900	67,548
Repurchase of Common Stock to Pay Employee Withholding Taxes	(279,347)	0
Cash Provided By Financing Activities	21,084,876	22,003,499
(Decrease) Increase In Cash and Cash Equivalents	(10,919,454)	14,307,063
Cash At Beginning Of Period	22,713,980	8,406,917
Cash At End Of Period	11,794,526	22,713,980
Supplemental Disclosure of Noncash Investing Activities:
Change in Unrealized Gain on Marketable Securities Available-for-Sale	(10,395)	109,293
Research and Development Licenses (Related Party)	0	850,000
Insurance Financing Note Payable	763,422	0
Public-offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering	18,777,642	22,000,000
Offering Costs from the Issuance of Common Stock / Public Offering	(1,489,787)	(64,049)
At -the-market
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering	5,383,079	0
Offering Costs from the Issuance of Common Stock / Public Offering	$ (309,479)	$ 0